ClinicalTrials.gg
RecruitingNCT06102499Oxygap 2Updated Nov 5, 2026

Comparison of Pulse Oximetry (SpO2) With Different Oximeters and Arterial Saturation (SaO2): Oxygap2 Study

An observational study in Respiratory Failure, Hypoxemia and Hyperoxemia, sponsored by Laval University. Recruiting at 5 sites in 3 countries. Open to participants aged 0 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Laval University · Observational

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Nov 5, 2026First sites in Guadeloupe and TunisiaSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
0 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 94 studies in Respiratory Insufficiency with a site in Canada — 24 open to participants now, 29 under way, 1 of them phase 3. Respiratory Insufficiency · Canada.

Planned enrollment
8th of 28
250 · median 118
Started
2024
with 6 others
Observational
28 of 94
9 open now
Primary completion
2027-06
later than 21 of 28 live
Registered
82nd of 94
by date
Lead sponsor
8 of 94
Laval University

Among the 94 studies in Respiratory Insufficiency with a site in Canada, this one is the 8th largest by planned enrollment of the 28 observational ones that give a count, is one of 7 that started in 2024, is one of 28 observational ones, reaches primary completion later than 21 of the 28 other live ones, and was the 82nd registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

24 of the 94 studies in Respiratory Insufficiency with a site in Canada are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 0 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Respiratory Insufficiency with a site in Canada, or all of them as a file.
02

Study summary

The oximeter is used to monitor intensive care patients undergoing oxygen therapy. It indicates pulsed oxygen saturation (SpO2), a reflection of arterial oxygen saturation (SaO2) which enables detection of hypoxemia and hyperoxia, both deleterious state. Current SpO2 recommendations aim to reduce both risk of hypoxemia and hyperoxia. SpO2 is considered the 5th vital sign.

Current recommendations for SpO2 targets do not consider the variability of oximeters used in clinical practice. This variability and lack of specification represent an obstacle to an optimal practice of oxygen therapy.

Thus, this study aims to compare the SpO2 values of different oximeters (General Electric-GE, Medtronic, Masimo and Nonin) used in clinical practice with the SaO2 reference value obtained by an arterial gas in order to specify the precision and the systematic biases of the oximeters studied. This data will also make it possible to refine the recommendations concerning optimal oxygenation

03

Conditions studied

  • Respiratory Failure
  • Hypoxemia
  • Hyperoxemia
04

Who can participate

Ages eligible
0 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patient in ICU with arterial catheter already installed will be consider

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Adult population

Inclusion criteria

Inclusion Criteria:

  • ≥ 18 years old (adult population) -
  • Patients admitted to the Intensive Care Unit
  • Artery catheter already installed

Pediatric population

  • Below 18 years old
  • Patients admitted to the Intensive Care Unit
  • Artery catheter already installed

Exclusion criteria

Exclusion Criteria:

  • No or poor signal with the usual pulse oximeter/based on clinician judgment
  • High dose of vasopressors or inotropes (epinephrine or norepinephrine ˃ 1mcg/kg/min), shock state (lactates above 3 mmoles/L)
  • Pigmented nails or nail polish
  • Methemoglobinemia history
  • below 80 g/L
  • Patient in isolation (multi-resistant bacteria, C-Difficile, SARS-COV-2…)
  • Prone position, Extra Corporel Membrane Oxygenator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pediatric population

    Pediatric population \< 18 years old (estimated 100 patients)

    Device: SpO2 and SaO2 comparison

  • Adult population

    Adult population \>or= 18 years old (estimated 150 patients)

    Device: SpO2 and SaO2 comparison

Interventions

  • DeviceSpO2 and SaO2 comparison

    Several pulse oximeter will be place on patient find few minutes before arterial blood gases. During an arterial blood sample, all SpO2 will be recorded

06

What researchers measure

Primary outcomes

  1. Difference between GE oximeter SpO2 value and the SaO2 value on arterial blood gases

    Difference between GE oximeter SpO2 and the SaO2 value

    Time frame: During procedure (arterial blood gas sample collection)

  2. Difference between Nellcor oximeter SpO2 value and the SaO2 value on arterial blood gases

    Difference between Nellcor oximeter SpO2 and the SaO2 value

    Time frame: During procedure (arterial blood gassample collection)

  3. Difference between Masimo oximeter SpO2 value and the SaO2 value on arterial blood gases

    Difference between Masimo oximeter SpO2 and the SaO2 value

    Time frame: During procedure (arterial blood gas sample collection)

  4. Difference between Nonin oximeter SpO2 value and the SaO2 value on arterial blood gases

    Difference between Nonin oximeter SpO2 and the SaO2 value

    Time frame: During procedure (arterial blood gas sample collection)

Secondary outcomes

  1. Overestimation and underestimation of SaO2

    Percent of pairs with overestimation and underestimation of SaO2 for each oximeter.

    Time frame: During procedure (arterial blood gas sample collection)

  2. Hypoxemia detection

    Ability to detect hypoxemia (SpO2 below 90% and PaO2 \< 60 mmHg)

    Time frame: During procedure (arterial blood gas sample collection)

Other outcomes

  1. Hyperoxemia detection

    Ability to detect hyperoxemia (SpO2 above 95% and PaO2 \> 100 mmHg)

    Time frame: During procedure (arterial blood gas sample collection)

  2. Gaps between the different oximeters

    Average of the SpO2 value gaps between the different oximeters tested

    Time frame: During procedure (arterial blood gas sample collection)

07

Study locations

2 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jun 2027, 36 months after the start.

Of 232 non-industry observational studies under Respiratory Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's planned 36 months is above that.

Counting every sponsor, half of 248 studies reached it within 22 months; a quarter within 12 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Jun 2026 → Jun 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2023
First posted
Oct 26, 2023
StartActual
Jun 20, 2024
Primary completionEst.
Jun 30, 2027was Jun 2026
CompletionEst.
Dec 30, 2027was Dec 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added — first sites in Guadeloupe and Tunisia. 3 sites changed recruiting status (2 now recruiting, 1 now completed)
Show 3 sites
  • CHUM · Montreal, CanadaRecruiting→Completed
  • CHU Ste-Justine · Montreal, CanadaNot yet recruiting→Recruiting
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec · Québec, CanadaNot yet recruiting→Recruiting
Show 2 added (1 Guadeloupe, 1 Tunisia)
  • CHU de la Guadeloupe · Les Abymes, Guadeloupe
  • Hôpital Universitaire Farhat Hached, · Sousse, Tunisia
Nov 5, 2026
Primary completion
Jun 30, 2026→Jun 30, 2027
Nov 5, 2026
Study completion
Dec 30, 2026→Dec 30, 2027
Nov 5, 2026
Enrollment
200→250
Nov 5, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • CHUM · Montreal, CanadaContact removed e•••@umontreal.ca · •••8000
  • CHU Ste-Justine · Montreal, CanadaContact p•••@ssss.gouv.qc.ca→M•••@ssss.gouv.qc.ca · •••4931Contact removed (no phone or email listed)
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec · Québec, CanadaContact none listed→•••8711
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    2 sites added — first sites in Guadeloupe and Tunisia. 3 sites changed recruiting status (2 now recruiting, 1 now completed)
    Show 3 sites
    • CHUM · Montreal, CanadaRecruiting→Completed
    • CHU Ste-Justine · Montreal, CanadaNot yet recruiting→Recruiting
    • Institut Universitaire de Cardiologie et de Pneumologie de Québec · Québec, CanadaNot yet recruiting→Recruiting
    Show 2 added (1 Guadeloupe, 1 Tunisia)
    • CHU de la Guadeloupe · Les Abymes, Guadeloupe
    • Hôpital Universitaire Farhat Hached, · Sousse, Tunisia
    Primary completion Jun 30, 2026→Jun 30, 2027
    Study completion Dec 30, 2026→Dec 30, 2027
    Enrollment 200→250
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • CHUM · Montreal, CanadaContact removed e•••@umontreal.ca · •••8000
    • CHU Ste-Justine · Montreal, CanadaContact p•••@ssss.gouv.qc.ca→M•••@ssss.gouv.qc.ca · •••4931Contact removed (no phone or email listed)
    • Institut Universitaire de Cardiologie et de Pneumologie de Québec · Québec, CanadaContact none listed→•••8711
    + 3 other changes: verification date, oversight details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06102499
Lead sponsor
Laval University
Responsible party
François Lellouche (Principal Investigator, Laval University) — Principal investigator
First posted
Oct 26, 2023
Start date
Jun 20, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Nov 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion